[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Madagascar\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":221},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,76,112,135,151,170,198],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100373655","phase-3-intensified-tuberculosis-treatment-to-reduce-the-mortality-of-patients-with-tuberculous-meningitis-100373655",false,"NCT04145258","Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)","INTENSE-TBM","Inclusion criteria:\n\n1. Age ≥ 15 years\n2. TBM defined as \"definite\", \"probable\" or \"possible\"\n3. Signed Informed Consent\n\n   * Definite TBM = at least one of the following criteria: acid-fast bacilli seen in CSF microscopy, positive CSF M. tuberculosis culture, or positive CSF M. tuberculosis commercial nucleic acid amplification test.\n   * Probable TBM = total modified Marais score ≥12 when neuroimaging is available, or ≥10 when neuroimaging is not available (at least 2 points should come from CSF or cerebral imaging criteria).\n   * Possible TBM = total modified Marais 6-11 when neuroimaging is available, or 6-9 when neuroimaging is not available.\n\nExclusion criteria:\n\n* \\> 5 days of TB treatment\n* Renal failure (eGFR\\\u003C30 ml\u002Fmin, CKD-EPI formula).\n* Neutrophil count \\\u003C 0.6 x 109\u002FL.\n* Hemoglobin concentration \\\u003C 8 g\u002FdL.\n* Total bilirubin \\> 2.6 times the Upper Limit of Normal\n* Platelet count \\\u003C 50 x 109\u002FL.\n* ALT \\> 5 times the Upper Limit of Normal.\n* Clinical evidence of liver failure or decompensated cirrhosis.\n* For women: more than 17 weeks pregnancy or breastfeeding.\n* For patients without decrease level of consciousness (Glasgow Coma Scale = 15): Peripheral neuropathy scoring Grade 3 or above on the Brief Peripheral Neuropathy Score (BPNS).\n* Documented M. tuberculosis resistance to rifampicin.\n* Positive gram-stain, bacterial culture or cryptococcal antigen in the Cerebral Spinal Fluid.\n* Evidence of active bleeding (hemoptysis, gastrointestinal bleeding, hematuria, intracranial bleeding).\n* Inability to collect Cerebral Spinal Fluid, except for patients with confirmed tuberculosis (by rapid molecular test or culture) from another biological sample and clinical and\u002For CT scan evidence of meningitis.\n* Major surgery within the last two weeks prior to inclusion.\n* Ongoing chronic aspirin treatment (eg for cardiovascular risk).\n* Current use of drugs contraindicated with study drugs and that cannot be safely stopped (see Appendix 1: Drugs contra-indicated with study drugs).\n* In available history from patients:\n\n  * Evidence of past intracranial bleeding.\n  * Evidence of past of peptic ulceration.\n  * Evidence of recent (\\\u003C 3 month) gastrointestinal bleeding.\n  * Known hypersensitivity contraindicating the use of study drugs .\n  * Evidence of porphyria.\n  * Evidence of hyperuricemia or gout.\n* Any reason which at the discretion of the investigator would compromise safety and cooperation in the trial.","ALL","15 Years",{"count":20,"type":21},768,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults with or without HIV-infection in sub-Saharan Africa:\n\n* Intensified TBM treatment with high-dose rifampicin and linezolid, compared to WHO standard TBM treatment.\n* Aspirin, compared to not receiving aspirin. The trial will be open-label for anti-TB treatment and placebo-controlled for aspirin treatment.",[27],"Tuberculous Meningitis",[27,29,30,31,32,33],"Intensified treatment","High dose Rifampicin","Linezolid","Aspirin","Subsaharan Africa","RECRUITING","2026-06-21",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"2021-02-07",{"date":42,"type":21},"2026-09-26",{"name":44,"class":45},"ANRS, Emerging Infectious Diseases","OTHER_GOV",13,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100606215","phase-2-efficacy-and-safety-study-of-dovramilast-in-people-with-leprosy-type-2-reaction-100606215","NCT07172659","Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction","A 12-week, Open-label, Randomized, Standard of Care Controlled, Dose-ranging Safety and Efficacy Study of Dovramilast in People With Moderate to Severe Acute or Recurrent Leprosy Type 2 Reaction","Inclusion Criteria:\n\n1. Aged 18 years of age or older.\n2. Provision of written informed consent.\n3. Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.\n4. Leprosy type 2 reaction meeting the following criteria:\n\n   * Either:\n\n     i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).\n   * Presence of at least 10 leprosy type 2 reaction tender papular and\u002For nodular skin lesions (not including scars).\n   * An ENLIST score of at least 9.\n5. If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.\n6. If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.\n\nExclusion Criteria:\n\n1. Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been \\\u003C 28 days.\n2. Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (\\> 50 mg\u002Fday), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive\u002Fimmunomodulatory treatment within 28 days of Baseline.\n3. Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).\n4. Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).\n5. Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.\n6. Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.\n7. Active systemic fungal infection requiring or undergoing treatment.\n8. Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.\n9. Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.\n10. Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.\n11. Pregnant women or breastfeeding mothers.\n12. Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme or use (or planned use) of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem. Substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp should be used with caution when concomitantly administered with dovramilast.\n13. Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.\n14. Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.\n15. Current diagnosis of depression, and\u002For history of suicide ideation\n16. History of or presence of cardiac disease, including:\n\n    * Clinically significant abnormal electrocardiogram\n    * QTcF \\> 450 msec\n17. Receipt of a vaccination within 7 days of Baseline.\n18. Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.\n19. Body Mass Index \\\u003C 15 kg\u002Fm\\^2 or \\> 35 kg\u002Fm\\^2.\n20. Unable to, or significant difficulty with, swallowing tablets\u002Fcapsules.\n21. Anemia requiring transfusion.\n22. History of or current pancreatitis.\n23. Known or suspected cirrhosis of the liver.\n24. The following laboratory abnormalities:\n\n    * White blood cells (WBC) \\\u003C 2.5 x 10\\^9\u002F L.\n    * Neutrophils (granulocytes) \\\u003C 1.0 x 10\\^9\u002FL.\n    * Platelets \\\u003C 80 x 10\\^9\u002FL.\n    * Aspartate aminotransferase or alanine aminotransferase \\> 2 times the upper limit of reference range.\n    * Albumin \\\u003C 30 mg\u002FdL.\n    * Bilirubin \\> 2 mg\u002FdL\n    * Calculated creatinine clearance (Cockcroft Gault) \\\u003C 50 milliliter (mL)\u002Fminute.\n    * Lipase ≥ 1.6 times the upper limit\n25. Previous participation in this study\n26. Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments\n27. Enrolled in another leprosy type 2 reaction treatment study","18 Years",{"count":56,"type":21},45,[58],"PHASE2","Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.",[61],"Erythema Nodosum Leprosum",[63,64],"Leprosy type 2 reaction","dovramilast","2026-05-21",{"date":67,"type":38},"2026-05-26",{"date":69,"type":21},"2026-05-25",{"date":71,"type":21},"2027-12",{"name":73,"class":74},"Medicines Development for Global Health","OTHER",6,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100587069","phase-3-serological-testing-and-treatment-for-plasmodium-vivax-malaria-a-trial-in-ethiopia-and-madagascar-100587069","NCT06923592","Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","Serological Testing and Treatment for Plasmodium Vivax Malaria: a Cluster-Randomised Trial in Ethiopia and Madagascar","PvSTATEM","Inclusion Criteria:\n\n* Participant will remain in the study area for at least the next month.\n* Participant is older than 12 months\n\nExclusion Criteria:\n\n• Participant is unwilling to participate.","12 Months",{"count":86,"type":21},19200,[24],"The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria (relapses) and ongoing parasite transmission. Relapses account for a majority of recurrent infections and clinical cases of P. vivax malaria, and therefore have a significant effect on morbidity at the individual level.\n\nWith current technology, it is not possible to directly measure hypnozoite biomarkers. Rather than directly detecting hypnozoites, our team developed an indirect approach by measuring antibodies induced by the primary blood-stage infection. Antibodies to different blood-stage antigens decay at different rates. Measuring antibodies to a carefully selected panel of P. vivax antigens can aid to identify individuals who have been infected within the previous 9 months (approximately the lifespan of hypnozoites).\n\nA serological test based on selected P. vivax antigens can detect recent exposure and predict future relapses. Coupling this test with a safe and efficacious primaquine treatment regimen, results in a population-based intervention to target the hypnozoite reservoir. This intervention is referred to as Plasmodium vivax Serological Testing and Treatment (PvSeroTAT).\n\nPvSTATEM is a cluster randomised trial in Madagascar and Ethiopia. This study will provide insights into the feasibility, acceptability, and efficacy of the PvSeroTAT approach. In this study, individuals, randomised by clusters, will be tested for the presence of serological markers of a recent P. vivax infection, followed by a targeted drug treatment intervention aimed at killing P. vivax hypnozoites.",[90,91,92,93],"Malaria Vivax","Malaria Falciparum","Plasmodium Vivax","Plasmodium Falciparum",[95,96,97,82,98,99,100,101],"Plasmodium vivax","Vivax","PvSeroTAT","Primaquine","serology","Cluster randomised trial","G6PD","2026-03-19",{"date":104,"type":38},"2026-03-24",{"date":106,"type":38},"2025-05-12",{"date":108,"type":21},"2027-04-28",{"name":110,"class":74},"London School of Hygiene and Tropical Medicine",2,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":54,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100395158","therapeutic-recommendations-for-the-treatment-of-children-with-a-retinoblastoma-100395158","NCT04425434","Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma","GFARB12019","Inclusion Criteria:\n\n* Unilateral intraocular Retinoblastoma (RB)\n* Unilateral extraocular intraorbital (RB)\n* Bilateral intraocular (RB)\n* bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side.\n\nExclusion Criteria:\n\n* Externalized tumor mass\n* massive extension to optic nerve up to optical channeltumor\n* intracranial extension leptomeninges\n* cerebral parenchyma\n* extension to regional lymph nodes and\u002For remote metastases.\n* cerebrospinal fluid involvement.\n* Trilateral RB\n* Incapacity to followed the whole treatement.",{"count":120,"type":21},3000,"OBSERVATIONAL","As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and early implementation of this protocol of therapeutic recommendations for treatment.",[124],"Retinoblastoma","2026-02-27",{"date":127,"type":38},"2026-03-02",{"date":129,"type":38},"2020-11-01",{"date":131,"type":21},"2030-12-31",{"name":133,"class":74},"French Africa Pediatric Oncology Group",7,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":54,"enrollmentInfo":142,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":149,"leadSponsor":150,"locationsCount":134},"100395157","recommendations-for-the-treatment-of-children-with-burkitts-lymphoma-100395157","NCT04425421","Recommendations for the Treatment of Children With Burkitt's Lymphoma","GFALMB2019","Inclusion Criteria:\n\nClinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.\n\n\\-\n\nExclusion Criteria:\n\nNot a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.",{"count":143,"type":21},1000,"This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.",[146],"Burkitt Lymphoma",{"date":127,"type":38},{"date":129,"type":38},{"date":131,"type":21},{"name":133,"class":74},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":54,"enrollmentInfo":160,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":134},"100395008","therapeutic-recommendations-for-nephroblastoma-100395008","NCT04423484","Therapeutic Recommendations for Nephroblastoma","Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.","GFANEPHRO20","Inclusion Criteria:\n\nUnilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.\n\n.\n\nExclusion Criteria:\n\nBilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal","6 Months",{"count":143,"type":21},"The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.",[163],"Nephroblastoma",{"date":127,"type":38},{"date":166,"type":38},"2020-07-01",{"date":168,"type":21},"2030-12-30",{"name":133,"class":74},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":176,"sex":17,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100626711","impact-of-a-cricket-and-black-soldier-fly-larvae-fortified-cracker-on-the-gut-microbiome-and-iron-status-in-malagasy-schoolchildren-100626711","NCT07439185","Impact of a Cricket and Black Soldier Fly Larvae-Fortified Cracker on the Gut Microbiome and Iron Status in Malagasy Schoolchildren","Inclusion criteria for children\n\n* Child (male, female, intersex, non-binary), aged 9 to 13 years old who attends one of the selected schools\n* Caregiver or legal guardian is willing to provide informed consent\n* Child is willing to provide informed assent\n\nExclusion criteria for children\n\n* Child age is outside the preferred age range (9 to 13 years)\n* Not enrolled in the participating schools\n* Unable or unwilling to comply with the study requirements\n* Illness requiring medical treatment, malaria, severe anemia (hemoglobin (Hb) concentration below 8.0 g\u002FdL as indicated by HemoCue 201+ system), severe acute malnutrition, fever, diarrhea, etc.\n* Covid-exposure or symptoms: loss of smell or taste\n* History of food allergies or adverse reactions to any edible insects\n* Chronic severe medical condition or congenital anomalies requiring frequent medical attention or interfering with dietary consumption\n* Caregiver does not give consent, or child does not assent\n\nInclusion criteria for parents • Willing to participate in completing surveys about demographics and household dynamics (assets, housing structure, etc.)\n\nExclusion criteria for parents\n\n• Caregiver does not consent to participate",true,"9 Years","13 Years",{"count":180,"type":21},650,[182],"NA","The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar.\n\nSpecifically, in this RCT, the investigators will assess whether the insect-fortified crackers can improve the health status of Malagasy school children. The investigators' objectives are to: (1) Assess changes in gut microbiome composition that occur after 6 and 14 weeks of cracker consumption through 16S rRNA sequencing. (2) Assess changes in intestinal and systemic inflammation after 6 and 14 weeks of cracker consumption through quantification of fecal calprotectin, lactoferrin, myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT) and circulating pro-inflammatory cytokines. (3) Assess changes in iron status after 14 weeks of cracker consumption through quantification of hemoglobin (Hb), inflammation-adjusted serum ferritin, and soluble transferrin receptor (sTfR).",[185,186,187],"Gut -Microbiota","Inflamation","Iron Absorption","NOT_YET_RECRUITING","2026-02-23",{"date":125,"type":38},{"date":192,"type":21},"2026-02",{"date":194,"type":21},"2026-06",{"name":196,"class":74},"Cornell University",1,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":206,"maxAge":54,"enrollmentInfo":207,"targetDuration":84,"studyType":121,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},"100347437","hospital-based-registry-of-childhood-cancer-in-pediatric-oncology-units-in-french-speaking-africa-100347437","NCT03803735","Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa","French African Pediatric Oncology Registry","RFAOP","Inclusion Criteria:\n\n1. Any child presenting at any one of the participating units for treatment\n2. Any child with any type of cancer\n3. Any child or adolescent less than 18 years of age.\n\nExclusion Criteria:\n\n1. No cancer found\n2. Age greater than 18 years -","1 Day",{"count":208,"type":21},10000,"The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population.\n\nCollecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.",[211],"Pediatric Cancer","2025-09-29",{"date":214,"type":38},"2025-10-03",{"date":216,"type":38},"2016-01-01",{"date":218,"type":21},"2030-12",{"name":133,"class":74},14,""]